Pixium Vision SA (0QVB.L)
| Previous close | 0.5250 |
| Open | 0.5185 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 0.5185 - 0.5185 |
| 52-week range | 0.5185 - 0.5185 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 40.108M |
| Beta (5Y monthly) | 1.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
Pixium Vision announces the availability of its audited financial statements for the financial year 2021
Pixium Vision announces the availability of itsaudited financial statements for the financial year 2021 Paris, 29 April 2022 – 7.00 p.m. CET - Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces that its audited financial statements for the year 2021 have been made available on the company’s website. The 2021 financial statements were app
- Globe Newswire
Results of Combined General Meeting held on April 19, 2022
Results of Combined General Meeting held on April 19, 2022 Annual General Meeting of Shareholders to be held on June 22, 2022 Paris, France, April 28, 2022 – 07:00 CET – The Combined Shareholders Meeting of Pixium Vision SA (Euronext Growth Paris - FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, was held in Paris on on April 19, 2022 and adopted all the resolutions pu
- Globe Newswire
Pixium Vision announces its cash position at 31 March 2022 and provides an update on its activities and financial outlook until the end of 2022
Pixium Vision announces its cash position at 31 March 2022 and provides an update on its activities and financial outlook until the end of 2022 Paris, France, April 19, 2022 – 07:00 CET– Pixium Vision SA (Euronext Growth Paris - FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independently, announces a cash position of €10.4 million at 31 March 2022 and reports on its key developments. In total, at 3
